Investigating how certain molecules affect the assembly of the HIV-1 virus
Official title: Structural and Biochemical Effects of Capsid-targeting Molecules on HIV-1 Capsid Assembly
Funded at Emory University · NIH-10995338 · Data updated 2026-11-12
This study is looking at how certain molecules can help stop the HIV-1 virus from making copies of itself, which could lead to better treatments for people living with HIV, including those with drug-resistant strains.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | December 29, 2022 |
| Project end | December 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $48,974 |
| NIH project number | 5F31AI174951-03 |
| Project ID | NIH-10995338 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who may be experiencing issues with current antiretroviral therapies or have developed drug-resistant strains of the virus.
✕Less likely to help
Patients who are not living with HIV or those who have not been affected by drug resistance may not benefit from this research.
What this research studies
This research focuses on understanding how specific molecules, known as capsid effectors, interact with the HIV-1 virus's capsid protein. By examining these interactions, the study aims to identify new potential treatments that could prevent the virus from replicating effectively. The approach involves characterizing structural changes in the virus when treated with these molecules and assessing their effectiveness against both standard and drug-resistant strains of HIV-1. This could lead to the development of more effective antiretroviral therapies for patients living with HIV.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antiretroviral drugs that are more effective against drug-resistant strains of HIV.
How similar studies have gone: Previous research has shown promise in targeting the HIV-1 capsid with similar approaches, indicating potential for success in this area.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Mcfadden, William Michael — Emory University
- Study coordinator: Mcfadden, William Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.